How to Finance a Compounding Pharmacy Acquisition

From SBA 7(a) loans to seller notes and equity rollovers — understand the capital structures that close compounding pharmacy deals in the lower middle market.

Find Compounding Pharmacy Deals SBA Calculator →

Compounding pharmacies trade at 3.5–6x SDE, placing most lower middle market deals between $1.75M and $6M. Financing is achievable but lender-specific: SBA 7(a) remains the dominant tool, though lenders scrutinize regulatory history, prescriber concentration, and USP 797/800 compliance before approving. Buyers should expect to layer SBA debt with a seller note and, in some cases, an earnout tied to prescriber retention.

Financing Options for Compounding Pharmacy Acquisitions

SBA 7(a) Loan

Up to $5MPrime + 2.75%–3.5% (currently ~10–11%)

The primary financing vehicle for compounding pharmacy acquisitions. Lenders require clean regulatory history, PCAB accreditation or documented USP compliance, and a licensed pharmacist-in-charge post-close.

Pros

Low down payment of 10–15% preserves working capital for compliance upgrades or cleanroom maintenance
Long 10-year amortization reduces monthly debt service pressure on pharmacy cash flow
SBA-approved lenders experienced in healthcare understand compounding pharmacy licensing requirements

Cons

×FDA 483 observations or state board sanctions can disqualify the deal or require costly escrow holdbacks
×Prescriber concentration above 30% in one physician may trigger lender concern or reduced loan-to-value
×Personal guarantee required; buyer's net worth and liquidity are fully scrutinized during underwriting

Seller Financing / Seller Note

$150K–$600K (10–20% of deal)6–8% fixed, 5–7 year term

Sellers carry 10–20% of the purchase price as a subordinated note, commonly used to bridge valuation gaps and signal seller confidence in prescriber relationship continuity post-transition.

Pros

Reduces upfront buyer cash requirement and demonstrates seller's confidence in post-close performance
Allows earnout-style structure tied to prescriber retention without complex earnout documentation
Flexible negotiation on deferral periods during ownership transition, easing early cash flow pressure

Cons

×Seller may demand higher purchase price in exchange for carrying financing, increasing total deal cost
×Conflict risk if buyer disputes regulatory or revenue issues discovered post-close while note is outstanding
×Subordinated to SBA debt, limiting seller's recourse if buyer defaults during transition period

Equity Rollover Structure

15–30% of equity retainedN/A — equity participation, no fixed rate

Seller retains a 15–30% minority equity stake post-close, often serving as pharmacist-in-charge during transition. Common in sterile compounding acquisitions where prescriber relationships are highly personal.

Pros

Seller remains pharmacist-in-charge, satisfying state board continuity requirements and protecting prescriber relationships
Aligns seller incentives with buyer success, reducing risk of prescriber attrition or staff departures
Reduces acquisition price and cash required at close while retaining operational expertise during transition

Cons

×Complex governance terms needed to define seller's ongoing role, exit rights, and drag-along provisions
×Seller may delay final transition, creating operational ambiguity around decision-making authority
×Minority stake valuation and buyout triggers must be negotiated carefully to avoid future disputes

Sample Capital Stack

$2,500,000 (PCAB-accredited compounding pharmacy, $500K SDE, 5x multiple)

Purchase Price

Approx. $26,500/month combined (SBA at 10.5% over 10 years + seller note over 5 years)

Monthly Service

Approximately 1.35x based on $500K SDE — meets typical SBA minimum of 1.25x with modest buffer

DSCR

SBA 7(a) loan: $2,000,000 (80%) | Seller note at 7%: $250,000 (10%) | Buyer equity/down payment: $250,000 (10%)

Model your own deal structure →

Lender Tips for Compounding Pharmacy Acquisitions

1Document USP 797/800 cleanroom certifications and any third-party compliance audits before approaching SBA lenders — clean regulatory files accelerate underwriting significantly.
2Prepare a prescriber concentration analysis showing no single referral source exceeds 25–30% of revenue; lenders will stress-test prescriber departure scenarios during credit review.
3Identify your pharmacist-in-charge succession plan before loan application — SBA healthcare lenders require confirmation that licensure requirements will be met at close.
4Request lender experience with pharmacy or healthcare acquisitions specifically; generalist SBA lenders often misunderstand compounding-specific risks, slowing approval or adding unnecessary conditions.

Frequently Asked Questions

Can I buy a compounding pharmacy with an SBA loan if I'm not a licensed pharmacist?

Yes, but you must hire or partner with a licensed pharmacist-in-charge at close. Some states require ownership involvement by a licensed pharmacist, so verify state board rules before structuring the deal.

How does FDA regulatory history affect compounding pharmacy financing?

Outstanding 483 observations, warning letters, or consent orders can disqualify SBA financing or require escrowed holdbacks. Lenders treat unresolved FDA correspondence as material risk to business continuity and loan repayment.

What SDE multiple should I expect to pay for a PCAB-accredited sterile compounding pharmacy?

PCAB-accredited facilities with sterile compounding capabilities and diversified prescriber bases typically trade at 4.5–6x SDE. Non-accredited or non-sterile operations generally range from 3.5–4.5x.

Is seller financing common in compounding pharmacy acquisitions?

Yes. Seller notes of 10–15% are standard, especially when prescriber relationships are a key value driver. Lenders often require seller participation as evidence the seller is committed to a successful ownership transition.

More Compounding Pharmacy Guides

Buy a Compounding Pharmacy Business →Valuation Guide →SBA Loan Guide →Deal Structure →Common Mistakes →SBA Calculator →Deal Structure Builder →

Ready to finance your Compounding Pharmacy acquisition?

DealFlow OS surfaces acquisition targets and helps you structure the deal. Free to join.

Start finding deals — free

No credit card required